Patient accrual complete in Provectus PH-10 Phase 2C clinical trial for treatment of

[News]

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis. PH-10, an aqueous hydrogel formulation of Rose Bengal disodium for topical administration to the skin, is being studied for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis.

More... (http://www.news-medical.net/news/20110524/Patient-accrual-complete-in-Provectus-PH-10-Phase-2C-clinical-trial-for-treatment-of-psoriasis.aspx)